Why Your Weight Stalled on GLP-1 Medication

Is a stall during treatment normal?

A stall on GLP-1 medication usually means four overlapping mechanisms are at work: water masking fat loss, the changing composition of the weight already lost, an appetite advantage that narrows over months rather than days, and a metabolism adapting to your new lower weight, plus a quieter fifth factor sitting inside your own decisions, what you drink. If the scale has frozen, the first thing to know is that the pivotal trials anticipated this. The results themselves remain remarkable by any earlier standard.

In the STEP 1 trial, Wilding and colleagues reported mean body weight falling 14.9% on semaglutide 2.4 mg versus 2.4% on placebo across 68 weeks, a gap of 12.4 percentage points. Those published curves were never straight lines downward, they bent and flattened as they approached their endpoint. A plateau arriving partway through treatment is written into that shape.

Kevin Hall's mathematical modeling analysis, published in the journal Obesity in 2024, examined exactly why such curves bend. His model found that GLP-1 receptor agonism substantially weakens the body's appetite feedback circuit, so the losing phase stretches longer before weight settles at a new equilibrium compared with restriction alone. He concluded that a plateau while treatment continues is physiology running its expected course, not evidence the medication quit. That reframing matters, because the story most people tell themselves when the scale freezes is that the drug stopped working.

The mechanics behind the stall

Water and glycogen mask fat loss

In the first weeks of eating less, much of what leaves the body is not fat. Kreitzman and colleagues documented in the American Journal of Clinical Nutrition that glycogen, the body's stored carbohydrate, is packaged together with three to four parts water, so mobilizing glycogen releases fluid along with it. Early scale drops and day-to-day swings largely track that water, not fat status, and refilled glycogen stores can push the number back up without any change in body fat. This is why a stretch of flat days can hide real progress, and why judging any single week misleads. Read the monthly trend instead.

Some of what you lost is lean mass, which changes what the scale means

Dubin and colleagues analyzed 28 trials of GLP-1 based medications and estimated that 20 to 40% of the weight lost was fat-free mass, which includes muscle along with the water bound to it, with most trials landing above 25%. A 2026 meta-analysis of randomized controlled trials by Eisa and Barood estimated the semaglutide-specific share at 35.2%. Two honest readings follow. First, the quality of loss is worth protecting, because muscle carries strength, energy, and long-term independence. Second, this does not mean lean tissue mechanically slows the scale, the stalling runs through appetite and adaptation, covered below. What it does mean is that two people showing identical scale numbers can carry very different bodies inside, which is exactly why the scale alone is the wrong scoreboard mid-treatment.

The appetite advantage narrows over months, not days

Hall's model supplies the long arc: GLP-1 receptor agonism weakens the appetite feedback loop, it does not erase it, so intake drifts back toward balance as the body defends its new weight and the curve levels off. Human data point the same direction, with important limits. In a subgroup analysis from STEP 5, Wharton and colleagues reported that hunger and fullness improvements reached significance versus placebo at week 20 only, while craving-control measures remained significantly improved at weeks 20, 52, and 104. That subgroup counted just 88 participants and the analysis did not adjust for multiple comparisons, so the defensible summary is narrow: some eating-control effects may attenuate over long-term treatment even as others persist. Nothing here supports a stronger wear-off story on a short clock. Semaglutide's half-life runs roughly one week, between 145 and 168 hours according to a 2024 systematic review by Yang and colleagues, the pharmacology behind once-weekly dosing with relatively steady exposure across the week. The taper plays out over months, and its pace is individual.

Your body adapts to the lower weight

Losing weight changes the machinery doing the losing. Rosenbaum and Leibel documented adaptive thermogenesis in humans maintaining a reduced body weight: after loss, the body conserves, spending less on resting processes and everyday movement than a same-size person who never lost, a response that pushes back against further loss. This is general human physiology, worked out long before GLP-1 medications existed, and how strongly it expresses in people on these treatments is less well characterized. Its direction, though, is settled: each step down makes the next step slower, which is one more reason curves flatten with time on treatment.

The quietest lever: what you drink

One lever sits entirely within reach of your own decisions. In a classic feeding study, DiMeglio and Mattes served people matched carbohydrate loads as either soda or jelly beans and watched what happened at later meals: the solid loads were almost precisely compensated, later meals shrank to offset them, while the liquid loads produced essentially no compensation, and body weight rose only during the liquid stretch. Liquid sugar arrives without triggering the fullness accounting that solid food performs. One caution before applying this: there is no GLP-1-specific trial behind extending the finding to people on these medications, it is general satiety science, and it is presented here as exactly that. As a general satiety pattern, drinks are where quiet sugar slips in: sweetened coffee, juice, and soda deliver a full insulin load in a volume that barely registers as eating. Swap them for water, plain coffee or tea, or anything you chew, and the stall loses one of its quietest feeders.

What you can do about it

None of this asks you to fight the medication, it asks you to work the window it opens. The medication quiets appetite, your meals decide what the smaller amounts do hormonally.

• Keep your daily Weight Impact average under 5. The WI Score estimates each meal's likely insulin impact from the meal itself, its ingredients, structure, and preparation, on a 1 to 10 scale. A daily average under 5 keeps insulin low enough that fat-burning runs for most of the day, the same destination the medication reaches from the appetite side. One photo per meal produces the score, and the weekly trend tells you more than any single scan.
• Pair adequate protein with resistance activity. In Eisa and Barood's meta-analysis, groups combining lifestyle change with resistance training lost the smallest share of their weight as lean mass, 17.5%, versus 26.2% for lifestyle-only groups. Adequate protein alongside resistance activity is associated with better lean-mass preservation. Treat that as an association to act on rather than a prescription: anchor every meal with a protein food you genuinely enjoy, eggs at breakfast, chicken in a proper salad, salmon at dinner.
• Protect the fasting window between meals. Insulin gets room to fall in the gaps between eating occasions, so give each meal a real finish and let the overnight fast run long. The app models your fat-burning timeline from your logged meals alone and shows where those gaps open up.
• Route every dose question to your prescriber. If the stall has you wondering whether the medication plan itself should change, that thought deserves the exam room, not a web page, and certainly not this one.

Stalling during treatment is not regaining after stopping

These are different events, and mixing them up manufactures unnecessary panic. In the STEP 4 trial, Rubino and colleagues followed participants who had reached semaglutide 2.4 mg after a 20-week lead-in, by which point they had already lost an average of 10.6% of their body weight. Over weeks 20 to 68, those who continued on the medication lost a further 7.9%, while those switched to placebo regained 6.9%, roughly two-thirds of what they had lost. Label that correctly as discontinuation data, it describes what stopping does, and it says nothing about a pause while still taking the medication. For the long view in the other direction, Garvey and colleagues reported in STEP 5 that participants remaining on semaglutide averaged 15.2% lower body weight at week 104 versus 2.6% on placebo, loss still accumulating across two years of continued treatment.

When to talk to your prescriber

Every decision about dose, titration schedule, injection timing, or switching medications belongs to your prescriber, and nothing in this article substitutes for their judgment. What you bring to the appointment is data. Honest triggers for the conversation: the scale truly stuck well past normal fluctuation despite low-insulin meals and protected fasting windows, signs of rapid muscle loss such as shrinking strength or stamina, side effects that interfere with daily life, or simply worry that will not settle, reassurance is a legitimate outcome of an appointment. Bring your meal patterns and your trend line, ask what the plan expects at your stage of treatment, and let the medication decisions stay clinical while the food decisions stay yours.

Ready to stop guessing what to eat?

Common questions

Why did my weight loss stall on Ozempic?

Most stalls come down to four overlapping mechanisms: water masking fat loss, the changing makeup of the weight you have lost, an appetite advantage that narrows over months, and metabolic adaptation to your lighter body, plus a fifth lever entirely within your control, what you drink. None of them signals failure, Hall's modeling analysis concluded that a plateau during continued treatment is the expected shape of the GLP-1 curve. What stays in your hands is meal quality: keep your daily Weight Impact average under 5, pair adequate protein with resistance activity, and protect the fasting window. Questions about the medication itself belong with your prescriber.

Why am I not losing weight on semaglutide?

A steady scale can hide falling fat, because day-to-day weight reflects water and stored carbohydrate far more than fat stores. Kreitzman's classic analysis showed glycogen is stored together with three to four parts water, so early loss and daily swings track fluid, not fat status. It also matters what the lost weight was made of: trials analyzed by Dubin and colleagues put 20 to 40% of GLP-1 weight loss at fat-free mass. If the scale stays flat for a stretch you consider genuinely long, take that specific question to your prescriber.

Is it normal to stop losing weight around week 6 on Wegovy?

Yes, slowing during the early weeks fits the normal shape of the curve, though the exact timing varies person to person. Loss tends to run fastest at the start, partly because water leaves alongside glycogen, then shifts to slower fat-led loss as treatment continues. Hall's modeling found that GLP-1 receptor agonism extends the losing phase before weight settles at a new equilibrium, and settling is built into the curve, not proof of failure. Whether your current plan matches where you are is a question only your prescriber can answer.

How long does a GLP-1 plateau last?

There is no fixed timeline in the research, because several clocks tick at once: water-masked progress can reappear on the scale quickly, the appetite taper unfolds over months, and adaptation sets in gradually as weight drops. On continued treatment the curve can keep descending for years, STEP 5 reported participants averaging 15.2% lower body weight at week 104 versus 2.6% on placebo. Judge your own trend over weeks and months rather than days, and let prescriber visits handle the medication side.

Has my Ozempic stopped working?

Probably not, because stalling during treatment and regaining after stopping are different events with separate data behind them. STEP 4 is discontinuation evidence: over weeks 20 to 68, participants who stayed on semaglutide lost a further 7.9% of body weight, while those switched to placebo regained 6.9%, roughly two-thirds of what they had lost. That trial describes what stopping does, it is not evidence about a pause while still taking the medication. Whether a medication plan needs adjusting is always a prescriber question.

When should you talk to your doctor about a weight-loss plateau?

Bring it up when the flat stretch outlasts normal fluctuation, when strength or energy falls quickly, or when side effects start steering your day. Every decision about dose, timing, or switching belongs to your doctor, so treat that appointment as the venue for every medication question. Between appointments, the levers you own are food quality, adequate protein plus resistance activity, and protected fasting windows. A plateau with mechanics behind it usually rewards patience plus those levers, and if yours does not, that too is useful information for your doctor.

Keep reading: how to break a weight loss plateau, what to eat on Ozempic and GLP-1, or how to lower insulin naturally.

Ozempic, Wegovy are trademarks of their respective owners. This comparison reflects publicly available information at the time of writing and is provided for informational purposes only. RealFoods is not affiliated with, endorsed by, or sponsored by any of the products mentioned. Feature sets and pricing change, verify current details on each product’s official website before making a purchasing decision.